The investment in China's pharmaceutical manufacturing industry is stable, and its core competitiveness is expected to improve

[pharmaceutical network industry trends] recently, the National Bureau of statistics issued a report on the achievements of economic and social development in the 70th anniversary of the founding of the people's Republic of China The report shows that since the founding of the people's Republic of China 70 years ago, the scale of fixed asset investment in China has been expanding, the investment structure has been gradually optimized, and the quality of investment has been continuously improved, and the trend of sustained and rapid growth has been maintained, with an average annual growth of 15.6% According to data statistics, from January to February 2019, the growth rate of China's fixed asset investment picked up steadily, with a total of 4484.9 billion yuan of fixed asset investment (excluding farmers), a year-on-year growth of 6.1%, 0.2% higher than that of last year Among them, manufacturing investment increased by 5.9% year-on-year Although the growth rate fell by 3.6% compared with the whole year last year, it was still higher than 1.6% in the same period last year Analysis of the reasons behind this is mainly due to the rapid growth of investment in transformation and upgrading of traditional manufacturing industry, especially in some manufacturing industries, including the investment in special equipment manufacturing industry, general equipment manufacturing industry, instrument and meter manufacturing industry, and pharmaceutical manufacturing industry, which increased by 16.3%, 12.7%, 12.6% and 10.5%, respectively As far as China's pharmaceutical manufacturing industry is concerned, this year's "tax reduction and fee reduction" policy enables pharmaceutical manufacturing enterprises to enjoy a real "dividend", especially bringing "timely rain" to small and micro enterprises, enabling them to invest more funds in production and operation, further expand production scale, increase research and development of new drugs, and increase profits of the company For example, in the VAT refund business handled by Guangzhou Huangpu District (Guangzhou Development Zone) Taxation Bureau, 30 enterprises, such as Weichuang Group Co., Ltd., which belong to the manufacturing industries of computer, communication and other electronic equipment, pharmaceutical manufacturing, etc., have obtained more than 200 million yuan of tax refund According to the industry, in the long run, the implementation of tax reduction and fee reduction policy can enhance the core competitiveness of pillar industries such as equipment manufacturing industry and pharmaceutical manufacturing industry, promote stable economic growth, and further promote the sustainable growth of fiscal revenue It is reported that in the second half of this year, the fiscal policy will still "strengthen and improve efficiency" The continuous implementation of tax reduction and fee reduction, as well as the continuous optimization of the financial expenditure structure will become the focus In addition, in the first half of this year, the science and technology innovation board has been promoted rapidly From the perspective of listing rules, the support of science and technology innovation board for the biomedical industry is relatively strong, which is conducive to the innovation and development of the pharmaceutical manufacturing industry As of June 16, there were 16 pharmaceutical manufacturing enterprises, accounting for 13%, second only to computer, communication and other electronic equipment manufacturing industries, software and information technology Science and technology innovation board has the "inclusiveness" that other plates do not have Among the accepted pharmaceutical manufacturing enterprises, for example, the listing standard selected by Suzhou Zejing biopharmaceutical is the fifth set, i.e the estimated market value is not less than 4 billion yuan, the main business or products need to be approved by the relevant departments of the state, and the market space is large At present, phased results have been achieved Pharmaceutical enterprises need to have at least one core product approved to carry out phase II clinical trials, and other enterprises that meet the positioning of scientific and technological innovation board need to have obvious technical advantages and meet the corresponding conditions In general, the current situation is conducive to the development of China's pharmaceutical manufacturing industry In addition, with the promotion of great health, China's fixed asset investment in pharmaceutical manufacturing will maintain stability, which will benefit the development of pharmaceutical manufacturing enterprises and is expected to enhance the core competitiveness Data shows that in 2018, the number of pharmaceutical manufacturing enterprises above Designated Size reached 7581, with sales revenue reaching 2.16 trillion yuan, up 12.4% year on year.